• PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
  • Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial
  • Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks
  • Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)